Inter Partes Review (IPR) challenges On 16 March 2023, Mylan Pharmaceuticals Inc. (Mylan) filed petitions for Inter Partes Review (IPR) against Novo Nordisk's semaglutide compound patents (US Patent Nos 8,129,343 and 8,536,122 expiring in 2026 and 2032, respectively) and a method of treatment patent (US Patent No 10,335,462 expiring in 2032). In October 2023, The U.S. Patent Office denied Mylan's petitions on the semaglutide compound patents, but granted the petition to institute review of the method of treatment patent. A hearing is scheduled for 9 July 2024 and a decision is expected later that year. Novo Nordisk is prepared to defend its intellectual property. Novo Nordisk does not expect these matters to have a material impact on Novo Nordisk's financial position, operating profit or cash flow.